ANTICUERPOS MONOCLONALES OPTIMIZADOS CONTRA EL INHIBIDOR DE LA VÍA DEL FACTOR TISULAR (TFPI)

Se proporcionan anticuerpos monoclonales aislados que se unen al inhibidor de la vía del factor tisular (TFPI)humano. También se contemplan las moléculas de ácido nucleico aisladas que codifican anticuerpos monoclonales que se unen al TFPI. También se proporcionan composiciones farmaceúticas que comprenden los anticuerpos monoclonales anti-TFPI y procedimientos de tratamiento de deficiencias o defectos en la coagulación mediante administración de los anticuerpos. También se proporcionan procedimientos para producir los anticuerpos. Monoclonal antibodies to human tissue factor pathway inhibitor (TFPI) are provided. Further provided are the isolated nucleic acid molecules encoding the same. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treatment of genetic and acquired deficiencies or defects in coagulations such as hemophilia A and B are also described. Also described are methods for shortening the bleeding time by administering an anti-TFPI monoclonal antibody to a patient in need thereof. Methods for producing a monoclonal antibody that binds human TFPI according to the present invention are also provided. In some embodiments, the monoclonal antibodies to TFPI provided have been optimized, for example to have increased affinity or increased functional activity.